Compare Organon & Co. Common Stock (OGN) vs Steel Dynamics Inc. (STLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Steel Dynamics Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Steel Dynamics Inc. trades at $244.39 (market cap $34.49B). The key difference: Steel Dynamics Inc. is far larger — about 9.5× Organon & Co. Common Stock's market cap, and Steel Dynamics Inc. pays the higher dividend (0.88%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Steel Dynamics Inc. for 6 Days on average.
| OGN | STLD | |
|---|---|---|
Market Cap | $3.62B | $34.49B |
Volume | 2,892,999 | 688,362 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $282.76 |
52-Week Low | $5.70 | $142.65 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $38.10B |
Dividend Yield | 0.58% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Steel Dynamics (STLD) trades at $240.63, up 0.62% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 7.83% net income margin and 17.58% ROE, with Q3 2026 earnings expected at $5.41 EPS. Recent news highlights anticipation for the upcoming earnings report on October 19, 2026.
The outlook is positive, supported by analyst consensus of a $271.17 price target and 'Moderate Buy' ratings. Risks include earnings volatility and steel market cyclicality, but revenue growth to $20.5B in 2026 and solid cash flow provide a foundation for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Steel Dynamics Inc.
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →
